|
1
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernardo GM and Keri RA: FOXA1: A
transcription factor with parallel functions in development and
cancer. Biosci Rep. 32:113–130. 2012. View Article : Google Scholar
|
|
4
|
Augello MA, Hickey TE and Knudsen KE:
FOXA1: Master of steroid receptor function in cancer. EMBO J.
30:3885–3894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katoh M, Igarashi M, Fukuda H, Nakagama H
and Katoh M: Cancer genetics and genomics of human FOX family
genes. Cancer Lett. 328:198–206. 2013. View Article : Google Scholar
|
|
6
|
Strazzabosco M: Foxa1 and Foxa2 regulate
bile duct development in mice. J Hepatol. 52:765–767. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Z, Merkurjev D, Yang F, Li W, Oh S,
Friedman MJ, Song X, Zhang F, Ma Q, Ohgi KA, et al: Enhancer
activation requires trans-recruitment of a mega transcription
factor complex. Cell. 159:358–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hurtado A, Holmes KA, Ross-Innes CS,
Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen
receptor function and endocrine response. Nat Genet. 43:27–33.
2011. View
Article : Google Scholar
|
|
9
|
Zaret KS and Carroll JS: Pioneer
transcription factors: Establishing competence for gene expression.
Genes Dev. 25:2227–2241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nucera C, Eeckhoute J, Finn S, Carroll JS,
Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al:
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin
Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin L, Miller CT, Contreras JI, Prescott
MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et
al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1),
on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279.
2002.PubMed/NCBI
|
|
12
|
Deutsch L, Wrage M, Koops S, Glatzel M,
Uzunoglu FG, Kutup A, Hinsch A, Sauter G, Izbicki JR, Pantel K and
Wikman H: Opposite roles of FOXA1 and NKX2-1 in lung cancer
progression. Genes Chromosomes Cancer. 51:618–629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gerhardt J, Montani M, Wild P, Beer M,
Huber F, Hermanns T, Müntener M and Kristiansen G: FOXA1 promotes
tumor progression in prostate cancer and represents a novel
hallmark of castration-resistant prostate cancer. Am J Pathol.
180:848–861. 2012. View Article : Google Scholar
|
|
16
|
Li Z, Tuteja G, Schug J and Kaestner KH:
Foxa1 and Foxa2 are essential for sexual dimorphism in liver
cancer. Cell. 148:72–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tong LL, Gao P, Wang ZN, Song YX, Xu YY,
Sun Z, Xing CZ and Xu HM: Is the seventh edition of the UICC/AJCC
TNM staging system reasonable for patients with tumor deposits in
colorectal cancer? Ann Surg. 255:208–213. 2012. View Article : Google Scholar
|
|
18
|
Huang W, Chen Z, Shang X, Tian D, Wang D,
Wu K, Fan D and Xia L: Sox12, a direct target of FoxQ1, promotes
hepatocellular carcinoma metastasis through up-regulating Twist1
and FGFBP1. Hepatology. 61:1920–1933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Avruch J, Zhou D and Bardeesy N: YAP
oncogene overexpression supercharges colon cancer proliferation.
Cell Cycle. 11:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barry ER, Morikawa T, Butler BL, Shrestha
K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et
al: Restriction of intestinal stem cell expansion and the
regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar :
|
|
21
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang
A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent
predictor of prognosis in colorectal cancer and related to the
proliferation and metastasis of colon cancer cells. PLoS One.
8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y and Li Z: Interplay of estrogen
receptors and FOXA factors in the liver cancer. Mol Cell
Endocrinol. 418:334–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reddy OL, Cates JM, Gellert LL, Crist HS,
Yang Z, Yamashita H, Taylor JA III, Smith JA Jr, Chang SS, Cookson
MS, et al: Loss of FOXA1 drives sexually dimorphic changes in
urothelial differentiation and is an independent predictor of poor
prognosis in bladder cancer. Am J Pathol. 185:1385–1395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horimoto Y, Arakawa A, Harada-Shoji N,
Sonoue H, Yoshida Y, Himuro T, Igari F, Tokuda E, Mamat O, Tanabe
M, et al: Low FOXA1 expression predicts good response to
neo-adjuvant chemotherapy resulting in good outcomes for luminal
HER2-negative breast cancer cases. Br J Cancer. 112:345–351. 2015.
View Article : Google Scholar :
|
|
25
|
Guo W, Keener AL, Jing Y, Cai L, Ai J,
Zhang J, Fisher AL, Fu G and Wang Z: FOXA1 modulates EAF2
regulation of AR transcriptional activity, cell proliferation, and
migration in prostate cancer cells. Prostate. 75:976–987. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qiu M, Bao W, Wang J, Yang T, He X, Liao Y
and Wan X: FOXA1 promotes tumor cell proliferation through AR
involving the Notch pathway in endometrial cancer. BMC Cancer.
14:782014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wierzbicki PM and Rybarczyk A: The Hippo
pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated
protein (YAP) gene expression in colorectal carcinoma cells. J Biol
Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Xie C, Li Q, Xu K and Wang E:
Clinical and prognostic significance of Yes-associated protein in
colorectal cancer. Tumour Biol. 34:2169–2174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang K, Zhou G, Zhang Q, Li J and Zhang
C: Expression of hippo pathway in colorectal cancer. Saudi J
Gastroenterol. 20:188–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang
X, Weng W, Pan Q, Yu Y, Sun F and Wang J: Tumor suppressor long
non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to
inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968.
2014. View Article : Google Scholar : PubMed/NCBI
|
